# LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

> **NCT05313529** · NA · ACTIVE_NOT_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 396 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Mild Cognitive Impairment

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Empagliflozin
- **DRUG:** Linagliptin

## Key facts

- **NCT ID:** NCT05313529
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-08
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05313529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05313529, "LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05313529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*